ÂÜÀòÂÒÂ×

Charles is a Vice President in the SV biotech team. He helps form and fund companies developing transformational new medicines, with a broad focus from new company creation to later stage opportunities. Charles serves as a board observer at Autifony Therapeutics, EnaraBio, Pulmocide, Imbria Therapeutics, and Mestag Therapeutics which he also helped incubate and launch. Charles identifies and evaluates new opportunities and advises portfolio company management on strategy, fundraising, and business development. Prior to joining SV, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences clients including SV portfolio companies.